[{"id":"202a63d1-07ad-43e6-b0e5-90f62602468d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04149613","created_at":"2021-01-18T20:15:40.071Z","updated_at":"2024-07-02T16:36:07.094Z","phase":"","brief_title":"Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer","source_id_and_acronym":"NCT04149613","lead_sponsor":"American University of Beirut Medical Center","biomarkers":" MIR155 • MIR200B • MIR21 • MIR200C • MIR126 • MIR210 • MIR31 • CRP • MIR19A • MIR203A • MIR29A • MIR345","pipe":"","alterations":" ","tags":["MIR155 • MIR200B • MIR21 • MIR200C • MIR126 • MIR210 • MIR31 • CRP • MIR19A • MIR203A • MIR29A • MIR345"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 05/25/2018","start_date":" 05/25/2018","primary_txt":" Primary completion: 12/18/2023","primary_completion_date":" 12/18/2023","study_txt":" Completion: 04/18/2024","study_completion_date":" 04/18/2024","last_update_posted":"2022-07-20"},{"id":"1022f5f1-1eb6-47b1-a7bc-74b7e5221109","acronym":"","url":"https://clinicaltrials.gov/study/NCT03416803","created_at":"2021-01-18T16:51:26.406Z","updated_at":"2024-07-02T16:37:14.188Z","phase":"","brief_title":"A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma","source_id_and_acronym":"NCT03416803","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" MIR31 • MIR145","pipe":"","alterations":" ","tags":["MIR31 • MIR145"],"overall_status":"Unknown status","enrollment":" Enrollment 150","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2018-02-05"},{"id":"730bb2bf-7f1f-47da-9f99-0163897882e2","acronym":"PETACC-8","url":"https://clinicaltrials.gov/study/NCT03362684","created_at":"2021-01-17T17:38:18.289Z","updated_at":"2024-07-02T16:37:15.843Z","phase":"Phase 3","brief_title":"PETACC-8 miR-31-3p and miR-31-5p Ancillary Study","source_id_and_acronym":"NCT03362684 - PETACC-8","lead_sponsor":"IntegraGen SA","biomarkers":" BRAF • RAS • MIR31","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF • RAS • MIR31"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 1808","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":" Completion: 06/30/2016","study_completion_date":" 06/30/2016","last_update_posted":"2017-12-05"}]